Stronger Equity Capital BaseA material increase in shareholders’ equity provides a larger capital cushion to fund R&D and regulatory processes over the coming months. That equity buffer reduces immediate insolvency risk, allowing the company to pursue clinical/commercial milestones before needing dilutive capital, supporting operational continuity.

Positive Gross Profit In Revenue YearsConsistently positive gross profit suggests the core product economics (per-dose consumable model) can yield margin once volumes scale. If SG&A and R&D can be controlled or allocated to growth phases, the underlying unit economics support a viable path to operating leverage after commercialization.

Scalable Medtech Revenue ModelA per-procedure consumable plus licensing/partnering model is structurally attractive for recurring revenue and margins in medtech. Partnerships can de-risk manufacturing, regulatory and distribution, enabling scale without full internal commercialization cost—durable structural upside if clinical success is achieved.

Bears Say

Persistent High Cash BurnSustained multi-year negative operating cash flows at tens of millions annually indicate continued dependence on external financing. That persistent burn increases dilution risk and constrains strategic flexibility, making long-term R&D and commercialization timelines vulnerable if funding terms worsen or access to capital tightens.

Collapse In Revenue And Weak Sales TractionA steep revenue decline to near-zero signals structural demand, commercialization, or recognition timing issues. For a clinical-stage medtech company, failing to convert limited early revenue into consistent sales raises execution risk and lengthens the time to reach sustainable volume, complicating cash flow recovery.

Sharp Increase In DebtA sudden rise in leverage materially increases financial risk for a loss-making developer. Debt servicing and covenant risk reduce runway and raise the chance of restrictive financing conditions. If commercialization timelines slip, higher leverage can force costly refinancing or accelerate dilution through urgent capital raises.

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr29.10 and its highest was kr47.60 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr542.80M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is Jun 03, 2026 which is in 89 days.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on Feb 25, 2026. The company reported -kr1.278 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.278.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.278 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.